Clinical Trial Update: PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 inhibitor with nab-paclitaxel and bevacizumab for cancer of unknown primary (CUP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary

Drugs mentioned

• Bevacizumab (bevacizumab)
• Nab-paclitaxel (paclitaxel protein-bound)
• PD-1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: Cancer of Unknown Primary | Phase 2 | Status: UNKNOWN